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The ESC guidelines help physicians to make decisions in their
practice, but do not override the responsibility of health
professionals to make decisions and to follow the rules and
regulations applicable to drugs and devices. The level of
evidence and the strength of recommendation are outlined
in Tables 1 and 2.
The Czech Society of Cardiology endorses ESC guidelines
and prepares condensed summaries (text o5000 words
plus selected tables and figures) from the original full text.For details and for references see the original ESC
document [1].2. Introduction
2.1. Definition of acute myocardial infarction
Acute myocardial infarction is defined as the evidence of
myocardial necrosis in a clinical setting consistent with
myocardial ischemia. Criteria are described in Table 3. Most
Table 2 – Levels of evidence.
Level of evidence A Data derived from multiple randomized clinical trials or meta-analyes
Level of evidence B Data derived from a single randomized clinical trial or large non-randomized studies
Level of evidence C Consensus of opinion of the experts and/or small studies, retrospective studies, registries
Table 3 – Universal definition of myocardial infarctiona.
 Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with atleast one value above the 99th percentile of the upper reference
limit together withe vidence of myocardial ischemia with at least one of the following:
J Symptoms of ischemia.
J New or presumably new significant ST-T changes or new bundle branch block (BBB).
J Development of pathological Q waves in the ECG.
J Imaging evidence of new loss of viable myocardium.
J Identification of an intracoronary thrombus by angiography or autopsy.
 Cardiac death (occurring before blood cardiac biomarkers values are released or in rare cases not collected) with symptoms suggestive of
myocardial ischemia, and presumably new ECG changes or new BBB.
a Excluding myocardial infarction associated with revascularization procedures or criteria for prior myocardial infarction. ECG ¼ electro-
cardiogram; BBB ¼ bundle branch block.
Table 1 – Classes of recommendations.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 – e 2 8 9 e275STEMI patients show a typical rise in biomarkers and pro-
gress to Q-wave infarction.2.2. Epidemiology of ST-segment elevation myocardial
infarction
Coronary artery disease accounts for 12.8% of all deaths. The
incidence of hospital admission for STEMI in Sweden is 66
STEMI/100,000/year, similar figures were reported in the
Czech Republic, Belgium and USA.
STEMI mortality is influenced mainly by age and Killip
class, other factors being time delay to treatment, mode of
treatment, prior myocardial infarction, diabetes, renal failure,
number of stenosed coronary arteries, ejection fraction. The
in-hospital mortality of unselected STEMI patients varies
between 6% and 14%.3. Emergency care
3.1. Initial diagnosis
A working diagnosis of STEMI is based on chest pain lasting
Z20 min, not responding to nitroglycerine. Important cluesare a history of CAD and pain radiation to the neck, lower jaw
or left arm. Some patients (more likely women, diabetic or
elderly) have atypical symptoms: nausea/vomiting, dys-
pnoea, fatigue, palpitations, syncope.
Timely diagnosis of STEMI is crucial (Table 4). A 12-lead
ECG should be obtained at first medical contact (FMC). ST-
segment elevations (STE) should be found in two contiguous
leads and beZ0.25 mV in menr40 years, 0.2 mV in men440
years, or Z0.15 mV in women in leads V2–V3; and/or
Z0.1 mV in other leads (in the absence of LV hypertrophy or
LBBB). In inferior STEMI it is advisable to record right
precordial leads (V3R and V4R—concomitant right ventricular
infarction). Isolated posterior myocardial infarction (ST segment
depression Z0.05 mV in leads V1–V3) should be treated as a
STEMI. The use of posterior leads (STE in V7–V9 Z0.05 mV
(Z0.1 mV in men o40 years) is recommended.
In patients with clinical suspicion of on-going myocardial
ischemia with new or presumed new LBBB, immediate reper-
fusion therapy is indicated. Prompt management should be
also considered when persistent ischaemic symptoms occur
in the presence of RBBB.
Ventricular pacing may prevent interpretation of ECG. Repro-
gramming the pacemaker may be considered in patients not
dependent on ventricular pacing.
Table 4 – Recommendations for initial diagnosis.
ECG¼electrocardiogram; FMC¼first medical contact; STEMI¼ST-segment elevation myocardial infarction.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 – e 2 8 9e276Patients without diagnostic ECG. It is important to repeat the
ECG (monitor ST segment). On-going suspicion of myocardial
ischemia is an indication for emergency coronary angiography
(Table 5)
Left main coronary obstruction. The presence of ST depression
40.1 mV in Z8 surface leads coupled with STE in aVR and/or
V1 suggests ischemia due to multivessel or left main cor-
onary artery obstruction.3.2. Relief of pain, breathlessness and anxiety
(Table 6) Pain leads to sympathetic induced vasoconstriction.
Opioids (e.g., morphine) are used (avoid intramuscular injec-
tions). Side effects of opioids include vomiting, hypotension/Table 5 – Atypical ECG presentations that deserve prompt man
myocardial ischemia.
 LBBB, RBBB
 Ventricular paced rhythm
 Patients without diagnostic ST-segment elevation but with persistent
 Isolated posterior myocardial infarction
 ST-segment elevation in lead aVR
ECG¼electrocardiogram; LBBB¼ left bundle branch block; RBBB¼right bu
Table 6 – Recommendations for relief of pain, breathlessness
i.v.¼ intravenous; SaO2¼saturated oxygen.
Table 7 – Cardiac arrest.
ECG¼electrocardiogram; FMC¼first medical contact; PCI¼percutaneo
infarction.bradycardia and respiratory depression (responds to nalox-
one 0.1–0.2 mg i.v.).
3.3. Cardiac arrest
(Table 7) Many deaths occur during first few hours due to
ventricular fibrillation. In resuscitated patients with STE on
ECG, immediate coronary angiography is indicated. For
details refer to ERC guidelines.
3.4. Pre-hospital logistics of care
3.4.1. Delays
The most critical time is the very early phase (risk of cardiac




us coronary intervention; STEMI¼ST-segment elevation myocardial
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 – e 2 8 9 e277possible. The early reperfusion is critical for myocardial salvage.
The treatment delays are index of quality of care; they should
be recorded in every hospital providing care to STEMI patients.
There are several components of delay in STEMI (Fig. 1):
Patient delay is the delay between symptom onset and FMC.
To minimize patient delay, the public should be aware of
symptoms of acute myocardial infarction and call to emer-
gency services. It may be wise to provide stable CAD patients
with a copy of their routine baseline ECG for comparison
purposes by medical personnel.
Delay between FMC and ECG diagnosis should be o10 min.
Delay between FMC and reperfusion therapy is a predictor of
outcomes. The goal should be FMC to wire passage into theFig. 2 – Pre-hospital and in-hospital management,
Fig. 1 – Components of delay in STEMI anculprit artery time r90 min (r60 min in high-risk cases with
large anterior infarcts presenting within o2 hs). If reperfu-
sion therapy is fibrinolysis, a goal is FMC to needle time
r30 min. In PCI-capable hospitals, the goal is a ‘door-to-
balloon’ delay r60 min.
Delay between symptom onset and reperfusion therapy is most
important, since it reflects total ischaemic time. It should be
reduced as much as possible.
3.4.2. Emergency medical system
Awell-trained EMS and a shared written STEMI management
protocol are critically important. Pre-hospital diagnosis,
triage and initial emergency treatment in the ambulanceand reperfusion strategies within 24 h of FMC.
d ideal time intervals for intervention.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 – e 2 8 9e278has been shown to be associated with greater use of reperfu-
sion therapies, reduced delays and improved clinical out-
comes. All ambulance personnel should be trained to
recognize acute myocardial infarction, administer oxygen,
relieve pain and provide basic life support. All emergency
ambulances should be equipped with ECG recorders, defi-
brillators and at least one person on board trained in
advanced life support. Ambulance staff should be able to
record an ECG for diagnostic purposes and either interpret it
or transmit it to a coronary care unit.3.4.3. Networks
Optimal STEMI treatment should be based on networks
between hospitals with various levels of technology, con-
nected by an efficient ambulance service. Cardiologists
should actively collaborate with emergency physicians. The
main features of such a network are:TDefinition of geographical areas of responsibility; Shared management protocols;
 Pre-hospital triage to the appropriate institutions, bypass-
ing non-PCI hospitals whenever primary PCI can be
implemented; At the PCI hospital the patient should immediately be
taken to the catheterization laboratory, bypassing the
emergency department or coronary care unit; Patients presenting to a non-PCI-capable hospital should
be immediately transported for primary PCI; If ambulance with a STEMI patient arrives at a non-PCI-
capable hospital, the ambulance should await the diag-
nosis and if STEMI is confirmed should continue to a PCI-
capable hospital.able 8 – Logistics of pre-hospital care.atically on a 24/7 basis for all STEMI patients. The populationPrimary PCI centres should perform the procedure system-
catchment area for network systems in European countries
offering primary PCI to the majority of their population is
0.3–1.0 million. In small service areas the experience may
be suboptimal due to an insufficient number of STEMI
patients.3.4.4. General practitioners
Consultation with a general practitioner (instead of a direct
call to the EMS) increases pre-hospital delay. Therefore, in
general, the public should be educated to call the EMS, rather
than the primary care physician, for symptoms suggestive of
myocardial infarction.3.4.5. Admission procedures
Candidates for primary PCI should be admitted directly to the
catheterization laboratory, bypassing the emergency depart-
ment and/or intensive coronary care unit. Patients who are
candidates for fibrinolysis should be treated directly in the
pre-hospital setting.3.4.6. Logistics
The patient should call central EMS number as soon as
possible after the onset of chest pain (Fig. 2). EMS dispatches
a fully equipped ambulance with personnel trained to inter-
pret 12-lead ECG. Once the ECG reveals ST-segment elevation
(or new or presumed new BBB), the nearest PCI hospital is
informed about the expected time of patient arrival. During
the ambulance transfer, the catheterization laboratory (incl.
staff) is prepared, allowing direct transfer of the patient to the
catheterization laboratory table. When the diagnostic ECG
Table 9 – Recommendations for reperfusion therapy.
BBB¼bundle branch block.
Table 10 – Summary of important delays and treatment goals in the management of acute STEMI.
Delay Target
Preferred for FMC to ECG and diagnosis r10 min
Preferred for FMC to fibrinolysis (‘‘FMC to needle’’) r30 min
Preferred for FMC to primary PCI (‘‘door to balloon’’) in
primary PCI hospitals
r60 min
Preferred for FMC to primary PCI r90 min (r60 min if early presenter with large area at risk)
Acceptable for primary PCI rather than fibrinolysis r120 min (r90 min if early presenter with large area at risk) if this target cannot
be met, consider fibrinolysis
Preferred for successful fibrinolysis to angiography 3–24 h
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 – e 2 8 9 e279has been done elsewhere (not by the EMS), the EMS is called
for transfer and the above chain follows (Table 8).
3.5. Reperfusion therapy
3.5.1. Restoring coronary flow and myocardial tissue
reperfusion
For patients with STEMI (or new or presumed new BBB)within
12 h of symptom onset, early reperfusion should be performed
as early as possible (Table 9).Reperfusion therapy should be
considered if there is clinical and/or electrocardiographic
evidence of on-going ischemia, even if symptoms started 412 h
before or when the pain and ECG changes have been
stuttering.
There is no consensus whether PCI is beneficial412 h from
symptom onset in the absence of clinical and/or electrocar-
diographic evidence of on-going ischemia. One small rando-
mized study has shown myocardial salvage and improved
4-year survival from primary PCI when performed 12–48 h
after symptom onset. The OAT trial found no benefit of routine
coronary intervention when performed 3–28 days after acute
myocardial infarction.
3.5.2. Selection of a strategy for reperfusion
Primary PCI is the preferred reperfusion strategy in STEMI when
performed within guideline mandated times by an experi-
enced team (Fig. 1). From any FMC location the transfer via
EMS to the PCI centre should be implemented immediately.
Hospitals with non-stop (24/7) PCI availability should use
primary PCI as a routine treatment. Randomized trials have
shown repeatedly that primary PCI is superior to hospital
fibrinolysis. If primary PCI cannot be performed within
120 min of FMC by an experienced team, fibrinolysis should
be considered, particularly if it can be given prehospital andwithin the first 120 min of symptom onset (Fig. 2). It should
be followed by rescue PCI or early routine angiography.
Long delays to primary PCI are associated with worse
clinical outcomes. The ‘PCI-related delay’ is the difference
between FMC to balloon inflation minus FMC to start of
fibrinolytic therapy. In the US registry, the mean PCI-related
time delay where mortality rates of the two reperfusion
strategies were comparable was calculated at 114 min.
Primary PCI should be performed within 90 min after FMC
in all cases (o60 min in patients presenting directly to PCI
centre). In early presenters with large myocardium at risk, the
delay should beo60 min. These target delays for primary PCI
are quality indicators and they differ from the maximal PCI-
related delay of 120 min, which is useful in selecting primary
PCI over immediate thrombolysis as the preferred mode of
reperfusion (Table 10).3.5.3. Primary percutaneous coronary intervention3.5.3.1. Procedural aspects of primary PCI. (Table 11) Only the
infarct-related artery should be treated during the initial
intervention. The only exception is cardiogenic shock with
multiple critical (Z90% or angiographically unstable) lesions
if ischemia persists after PCI of the culprit lesion.
The radial approach reduced the incidence of bleeding events
in ACS. Reduced mortality in STEMI was observed with radial
approach in the RIVAL and RIFLE-ACS trials. However the
results suggested that the benefit of radial access depends
upon the radial expertise of operators.
In primary PCI, drug-eluting stents (DES) reduce the risk of
repeat revascularization without influencing the risk of
death, myocardial infarction or stent thrombosis on long
term follow up.
Table 11 – Primary PCI: indications and procedural aspects.
Table 12 – Periprocedural antithrombotic medication in primary PCI.
ADP¼adenosine diphosphate; GP¼glycoprotein; i.v.¼ intravenous; lab¼catheterization laboratory; PCI¼percutaneous coronary intervention;
TIA¼transient ischaemic attack; UFH¼unfractionated heparin.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 – e 2 8 9e280The routine use of manual thrombus aspiration in the TAPAS
trial reduced one-year mortality. Mechanical thrombectomy
or embolic protection devices have not been found to provide
similar benefits. Several large randomized trials are currently
running to confirm the results of TAPAS.
The presence of residual thrombus and/or spasm can lead to
stent under-sizing (or otherwise suboptimal deployment),
which is a frequent cause for restenosis or stent thrombosis
in real-life practice. Intracoronary nitrates should be used
before the angiographic sequence used for stent size selection.3.5.3.2. Periprocedural pharmacotherapy. (Tables 12 and 13)
Patients undergoing primary PCI should receive three antith-
rombotic drugs (aspirin, ADP-receptor blocker, anticoagulant) as
early as possible before angiography.
Aspirin should preferably be given orally (150–300 mg, chew-
ing) to ensure complete inhibition of TXA2-dependent plate-
let aggregation, but may be given intravenously (80–150 mg)
in patients unable to swallow.
The preferred ADP-receptor blockers are prasugrel (60 mg
loading dose, 110 mg maintenance dose) or ticagrelor
Table 13 – Doses of antiplatelet and antithrombin co-therapies.
Doses of antiplatelet co-therapies
With primary PCI
Aspirin Loading dose of 150–300 mg orally or of 80–150 mg i.v. if oral ingestion is not possible followed by a maintenance dose
of 75–100 mg/day.
Clopidogrel Loading dose of 600 mg orally, maintenance dose of 75 mg/day.
Prasugrel Loading dose of 60 mg orally, maintenance dose of 10 mg/day. In patients with weight 60 kg, maintenance dose of
5 mg is recommended. In patients 75 years, prasugrel is generally not recommended but a dose of 5 mg should be
used if treatment is deemed necessary.
Ticagrelor Loading dose of 180 mg orally, maintenance dose of 90 mg b.i.d.
Abciximab Bolus of 0.25 mg/kg i.v. and 0.125 mg/kg/min infusion (maximum 10 mg/min for 12 h).
Eptifibatide Double bolus of 180 mg/kg i.v. (given in a 10-min interval) followed by an infusion of 2.0 mg/kg/min for 18 h.
Tirofiban 25 mg/kg over 3 min i.v., maintenance infusion of 0.15 mg/kg/min for 18 h.
Without reperfusion therapy
Aspirin Starting dose 150–500 mg orally.
Clopidogrel 75 mg/day orally.




70–100 U/kg i.v. bolus when no GP IIb/IIIa inhibitor is planned. 50–60 U/kg i.v. bolus with GP IIb/IIIa inhibitors.
Enoxaparin 0.5 mg/kg i.v. bolus
Bivalirudin 0.75 mg/kg i.v.bolus followed by i.v. infusion of 1.75 mg/kg/h for up to 4 h after the procedure as clinically warranted.
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is contraindicated in patients with prior stroke/transient
ischaemic attack and not recommended in patients Z75
years or with body weight o60 kg. The European label
suggests in these patients a maintenance dose of 5 mg.
Ticagrelor may cause transient dyspnoea not associated with
lung abnormalities and rarely leading to discontinuation.
Ticagrelor may cause asymptomatic bradycardia in the first
week of therapy. Neither prasugrel nor ticagrelor should be
used after previous haemorrhagic stroke and in liver disease.
When these agents are not available or if contraindicated,
clopidogrel 600 mg should be given, followed by 150 mg main-
tenance dose in the first week and 75 mg thereafter.
Anticoagulants for primary PCI include UFH, enoxaparin or
bivalirudin. UFH iv. bolus should be 70–100 U/kg when no
GPIIb/IIIa inhibitor is planned. There are no solid data to
recommend the use of ACT to tailor UFH dose. When
enoxaparin is used, iv. bolus 0.5 mg/kg should be followed by
s.c. treatment. Based on the ATOLL trial and on the consider-
able clinical experience with enoxaparin in other PCI settings,
enoxaparin may be preferred over UFH. One trial demon-
strated the superiority of bivalirudin over the combination of
UFHþGP IIb/IIIa inhibitor, a benefit driven by a marked
reduction in bleeding, associated with an initial increase in
stent thrombosis.
Trials performed before the DAPT era documented benefits
of GPIIb/IIIa inhibitors during primary PCI. The FINESSE trial
found that routine upstream abciximab before primary PCI
did not yield clinical benefit but increased bleeding risk. The
BRAVE-3 trial did not show benefit from abciximab in primary
PCI among patients pre-treated with 600 mg of clopidogrel.
Therefore, the current role of routine GPIIb/IIIa inhibitors in
primary PCI in the era of potent DAPT is questionable. Bailout
use of GPIIb/IIIa inhibitors with angiographic evidence of
large thrombus, slow or no-reflow and other thromboticcomplications is reasonable. The AIDA-4 trial found no
clinical benefit (but also no harm) with intracoronary route
of administration. Therefore, the iv. route remains the stan-
dard of care for administration of GPIIb/IIIa inhibitors.
Routine post-procedural anticoagulant therapy is not indicated
after primary PCI except when there is a separate indication
for either full-dose anticoagulation due to, for instance, atrial
fibrillation, mechanical valves, LV thrombus, or prophylactic
doses for prevention of venous thromboembolism in patients
requiring prolonged bed rest.
3.5.3.3. Prevention and treatment of microvascular obstruction
and no reflow.. Inadequate myocardial perfusion after suc-
cessful opening of the infarct related artery is referred to as
‘no-reflow’. The diagnosis of no-reflow: post-procedural TIMI
flowo3 or myocardial blush grade 0–1 or ST resolution within
4 h of the procedure o70%.There is no evidence that intra-
coronary vasodilators, iv. adenosine or abciximab affect
clinical outcomes in this setting. The best therapy appears
to be prevention of distal embolization by manual thrombus
aspiration.
3.5.4. Fibrinolysis and subsequent interventions
Due to the fact, that since 2002 thrombolysis for STEMI was
completely replaced by primary PCI in the Czech Republic,
this summary does not cover fibrinolysis and the readers are
advised to read the original ESC full text document for a
comprehensive information about this treatment strategy.
3.5.5. Revascularization strategy for STEMI with multivessel
disease
It is discouraged to perform PCI of non-culprit vessels in the
acute setting (exceptions: cardiogenic shock, continuous
ischemia). The best strategy for STEMI patients with multi-
vessel disease after primary PCI of the infarct-related artery is
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conservative approach (medical therapy after primary PCI and
another revascularization only with evidence of ischemia) or
a staged revascularization approach (PCI or CABG several days
or weeks after primary PCI). Heart team decision and appro-
priate informed consent is needed.3.5.6. Coronary bypass surgery and multivessel coronary
revascularization
The need for CABG in the acute phase of STEMI is rare. CABG
may be indicated in patients with patent infarct artery and
anatomy unsuitable for PCI (patency of this artery provides
time for surgery) or at the time of repair for patients with
mechanical complications.
Withholding ADP inhibitors for surgery. It is reasonable to
stop clopidogrel Z5 day before surgery, to stop prasugrel Z7
day before surgery; ticagrelor may be discontinued Z4 day
before surgery. It is reasonable to restart DAPT after CABG as
soon as considered safe in relation to bleeding risk.3.5.7. Non-reperfused patients.
When reperfusion therapy was not given, aspirin, clopidogrel
and anticoagulant (UFH, enoxaparin or fondaparinux) should
be given as soon as possible. Recommended doses are given
in Table 13.
Late PCI of an occluded infarct-related artery after myo-
cardial infarction in stable patients has no benefit overTable 14 – Management of hyperglycaemia in STEMI.
HbA1c¼haemoglobin A1c; STEMI¼ST-segment elevation myocardial inf
Table 15 – Logistical issues for hospital stay.optimal medical therapy. Thus, in patients presenting days
after the acute event with a completed myocardial infarction,
only those with recurrent angina or documented residual
ischemia and proven viability on non-invasive imaging in a
large myocardial territory may be considered for revascular-
ization when the infarct artery is occluded.3.6. Management of hyperglycaemia in the acute phase of
STEMI
Hyperglycaemia on admission in ACS patients is common
and is a predictor of mortality and in-hospital complications
both in diabetic and non-diabetic patients. Hyperglycaemia
predicts short-term prognosis (larger infarct size), whereas
elevated HbA1c is associated with long-term outcome. The
benefits of tight glucose control through i.v. insulin are not
established. Therefore, a ‘strict, but not too strict’ glucose
control in STEMI is reasonable (Table 14).4. Management during hospitalization and at
discharge
4.1. Coronary care unit logistics and monitoring
(Table 15) STEMI patients should be admitted to an intensive
cardiac care or coronary care unit (full description in ESCarction.
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reperfusion treatment.
ECG monitoring for arrhythmias and ST-segment devia-
tions should be continued for at least 24 h after symptom
onset in all STEMI patients. Further monitoring depends
upon perceived risk.
Patients with significant LV damage should rest in bed
before a first assessment of infarct extent and severity is
possible for detection of early heart failure and arrhythmias.
In uncomplicated cases, the patient can sit out of bed on the
first day. Ambulation can often start early (particularly in
patients treated via the radial access).
The optimal length of stay in the coronary care unit and
hospital should be determined individually. PAMI-II trial
showed that low-risk patients (aged o70 years, LV ejection
fraction445%, one- or two-vessel disease, successful PCI and
no persistent arrhythmias) could be discharged from hospital
at day 3. Nevertheless, early post-discharge consultations
should be offered.4.2. Risk assessment and imaging
(Table 16) Clinical indicators of high risk include older age,
fast heart rate, hypotension, Killip class4I, anterior infarc-
tion, previous infarction, elevated initial serum creatinine
and history of heart failure. All patients should have
measured the complete lipid profile, plasma glucose and
renal function at the index admission. LV function and the
risk of ischemia should be known before discharge. Addi-
tional arrhytmologic investigation is indicated in selected
patients.4.3. Assessment of myocardial viability
LV myocardial dysfunction may be due to necrosis (non-
viable), stunning or hibernation (viable) or to their combina-
tion. Positron emission tomography, single-photon emission
computed tomography, dobutamine stress echocardiography
or magnetic resonance imaging might be used for detection
of viable myocardium and indication for revascularisation.Table 16 – Summary of indications for imaging and stress tes
Echocardiography¼transthoratic echocardiography, or transoesophagea
segment elevation myocardial infarction.4.4. Long-term therapies for ST-segment elevation
myocardial infarction
Long-term management should be initiated during hospital
stay and continued in collaboration with primary care phy-
sicians (Table 17).4.4.1. Lifestyle interventions and risk factor control
Key lifestyle interventions include smoking cessation and
tight blood pressure control, advice regarding diet and weight
control, and the encouragement of physical activity.
Smoking cessation is potentially the most effective of all
secondary prevention measures and a cessation protocol
should be adopted by each hospital with continued support
during rehabilitation.
Diet and weight control—wide variety of foods is recom-
mended with adjustment of calorie intake, increased con-
sumption of fruit, vegetables, wholegrain cereals and bread,
fish, lean meat, low-fat dairy products, monounsaturated and
polyunsaturated fats; reduction of total fats and salt intake if
blood pressure is raised. Weight reduction is needed in
patients with body-mass index Z30 kg/m2 and/or waist
circumference in males/females above 102/88 cm.
Physical activity—exercise therapy (thirty minutes five
times per week) can reduce the anxiety, improves patient
self-confidence, endothelial function and collateralization
and reduces progression of coronary lesions and
thrombogenic risk.
Blood pressure control—in hypertensive patients, blood
pressure should be well controlled (systolic o140 mmHg but
not o110 mmHg.).
Psychosocial factor interventions—at least in elderly there
is evidence that stress management is useful with a strong
dose-response effect between attendance rate in the group
sessions and outcome rate
Exercise-based rehabilitation programme—in the modern
era exercise-based rehabilitation might reduce some clinical
outcomes, particularly re-infarction, and global cardiovascular
risk.
Resumption of activities—decisions should be individua-
lized based on left ventricular function, completeness of
revascularization and rhythm control.ting.
l; LV¼ left ventricular MRI¼magnetic resonance imaging; STEMI¼ST-
Table 17 – Routine therapies in the acute, subacute and long term phase of STEMI.
ACE¼angiotensin-converting enzyme; ACS¼acute coronary syndrom; ARB¼angiotensin receptor blocker; BMS¼bare metal stent; DAPT¼dual
antiplatelet therapy; DES¼drug-eluting stent; LDL¼ low-density lipoprotein; LV¼ left ventricular; STEMI¼ST-segment elevation myocardial
infarction.
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Table 18 – Treatment of heart failure and LV dysfunction.
ACE¼angiotensin-converting enzyme; ARB¼angiotensin receptor blocker; CABG¼coronary artery bypass graft; i.v.¼ intravenous; LV¼ left
ventricular; LVEF¼ left ventricular ejection fraction; PCI¼percutaneous coronary intervention.
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Aspirin—low doses (70–100 mg) are generally used indefi-
nitely. Patients with history of hypersensitivity to aspirin
can undergo desensitization, patients who are truly intoler-
ant to aspirin can receive clopidogrel (75 mg/day).
Duration of DAPT and antithrombotic combination thera-
pies after STEMI—dual antiplatelet therapy combining
aspirin and an ADP-receptor blocker (clopidogrel, prasugrel
or ticagrelor) is recommended in all patients for up to 12
months and needs to avoid premature discontinuation.
In patients with STEMI, atrial fibrillation and the need for
permanent anticoagulation after primary PCI ‘triple therapy’
is recommended. Selection of BMS over DES would minimize
its duration but should be weighed against the benefits of DES
in preventing restenosis.
Preferably proton pump inhibitor gastric protection should
be considered for patients with a history of gastrointestinal
bleeding, and is appropriate for patients with multiple risk
factors for bleeding.
The role of novel anticoagulants in combination with DAPT
in secondary prevention of STEMI remains debated (higher
clinical efficacy and serious bleeding in low-dose of rivarox-
aban added to aspirin and clopidogrel in ATLAS ACS 2-TIMI
51; no benefit of apixaban in the APPRAISE-2 trial and dose-
dependent increases in major bleeding without benefit of
darexaban and dabigatran).
4.4.3. Beta-blockers
Early oral administration of beta-blockers appears associated
with benefit, but early i.v. use of beta-blockers is contra-
indicated in patients with clinical signs of hypotension or
congestive heart failure.
4.4.4. Lipid-lowering therapy
High-dose statins (strongest data are for atorvastatin, 80 mg
daily) should be given to all patients with acute myocardialTable 19 – Management of atrial fibrillation.
Recommended doses of antiarrhythmic agents are given in guidelines f
CCB¼calcium-channel blocker; i.v.¼ intravenous; LoA¼ level of evidence
aCalcium antagonists should be used cautiously or avoided in patients winfarction, started early. The use of lower intensity statin
therapy should be considered in patients at increased risk of
side-effects. Lipids should be re-evaluated after 4–6 weeks
with an LDL-cholesterol concentration ofo1.8 mmol/L as the
goal. In patients intolerant of any dose of statin, ezetimibe
should be considered.4.4.5. Nitrates
Nitrates, valuable anti-anginal agents, are not routinely
recommended (intravenous may be useful in hypertensive
or heart failure patients without contraindications).4.4.6. Calcium antagonists
Not indicated in the acute phase. In the chronic phase and
contraindications to beta-blockers, verapamil may be helpful
(dihydropyridines only for hypertension or angina).4.4.7. Angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers
ACE inhibitors (alternatively valsartan 160mg twice daily) should
be given to patients with an ejection fractiono40% or who have
experienced heart failure in the early phase (not considered as
mandatory in all post-STEMI patients except with diabetes).
Patients who do not tolerate an ACE inhibitor should be given
an ARB.4.4.8. Aldosterone antagonists
Aldosterone blockademay be considered for post-STEMI patients
with an ejection fraction o40%, heart failure or diabetes (serum
creatinine in males/femaleso221/o177 mmol/L, potassiumo5.0
mEq/L). Routine monitoring of serum potassium is warranted.4.4.9. Magnesium, glucose–insulin–potassium, lidocaine
No benefit to the routine administration.or management of patients with atrial fibrillation(2 5 0).
; LV¼ left ventricular.
ith heart failure because of their negative inotropic effects.
Table 20 – Management of ventricular arrhythmias and conduction disturbances in the acute phase.
Recommended doses of antiarrhythmic agents are given in the guidelines for management of patients with ventricular arrhythmias and the
prevention of sudden cardiac death.
AV¼atrioventricular; i.v.¼ intravenous; ICD¼ implantable cardioverter defibrillator; LVEF¼ left ventricular ejection fraction; VF¼ventricular
fibrillation; VT¼ventricular tachycardia.
c QT-prolonging agents should not be used if baseline QT is prolonged.
d Intravenous sotalol or other beta-blockers should not be given if ejection fraction is low.
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elevation myocardial infarction
5.1. Haemodynamic disturbances: Heart failure and shock
(Table 18) Rapid improvement in ventricular function is
usually seen following early revascularization. However, if
the STEMI results in transmural injury and/or microvascular
obstruction, pump failure with pathological remodelling and
heart failure (HF) may complicate the acute phase and result in
chronic HF. LV dysfunction is the single strongest predictor of
mortality following STEMI. The degree of HF is categorizedaccording to the Killip classification. Cardiogenic shock (CS) com-
plicates 6–10% of STEMI with hospital mortality around 50%.
General measures include: thorough history, physical
examination and haemodynamic assessment (ECG, blood
pressure and oxygen saturation monitoring, hourly urinary
output). Chest X-ray assesses pulmonary congestion. Echo-
cardiography is crucial for the assessment of LV function and
volumes, valvular function, RV function and mechanical
complications detection. Deterioration of the patient’s clin-
ical status with haemodynamic compromise should trigger a
re-evaluation with a repeat echocardiography. In patients
with on-going ischemia, persistent ST elevation or new LBBB,
the need for further revascularization should be considered.
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class III).
Non-invasive ventilation is often effective. If not, endotra-
cheal intubation is indicated. Systolic arterial blood pressure
(BP) determines the choice of inotropic or vasopressor agent.
In patients with BP490 mmHg dobutamine or levosimendan
are given. Noradrenaline may be preferable in patients with
hypotension and signs of CS or septicaemia. Ultrafiltration to
reduce fluid overload refractory to diuretics may be useful.
5.1.2. Severe heart failure with cardiogenic shock (Killip
class IV)
Management of CS complicating STEMI includes haemody-
namic stability achieved with medical or mechanical circu-
latory support and emergent revascularization (PCI or CABG).
Early revascularization improves long-term survival. It is
essential to detect alternative causes of hypotension (hypo-
volemia, drugs, arrhythmias, tamponade, mechanical com-
plications or RV infarction).
Antithrombotics are given as in other STEMI patients; although
clopidogrel, prasugrel or ticagrelor should be deferred until
angiography (immediate CABG may be necessary).
Vasopressors and inotropes are used due to favourable
haemodynamic effects despite their possible deleterious
cellular effects. (Table 18) IABP is the most widely used
mechanical support. Conflicting evidence with respect to
the benefit of IABP in CS is related to the difficulty of
performing randomized trials in CS. Percutaneous LV assist
device may be considered in patients not responding to
standard therapy including inotropes, fluids and IABP.
5.2. Arrhythmias and conduction disturbances in the
acute phase
are common. Arrhythmias after the early reperfusion period
may be a manifestation of continuing myocardial ischemia,
pump failure, altered autonomic tone, hypoxia, electrolyte
and acid-base disturbances.
Atrial fibrillation (AF) is frequently associated with severe
LV damage. Table 19 summarizes the treatment. Because AF
will generally require anticoagulation, the benefits of DES on
restenosis should be weighed against the bleeding risks
(prolonged antiplatelet and anticoagulant therapy, for details
see guidelines on the management of AF)
Ventricular arrhythmias (Table 20) Ventricular tachycardia
should be differentiated from accelerated idioventricular
rhythm (o120 beats/min). Runs of non-sustained VT not
necessarily require treatment. Electrical cardioversion is
indicated if any VT persists and always if the patient is
haemodynamically unstable.
Ventricular fibrillation: immediate defibrillation should be
performed according to international guidelines. Indications
for ICD implantation are summarized in Table 20.
Sinus bradycardia and heart block (Table 20) First-degree
heart block needs no treatment.Second-degree Type I (Mobitz I or
Wenckebach) AV block or sinus bradycardia.
In hemodynamically unstable patients, i.v. atropine should
be given. If this fails, pacing should be instituted.
Second-degree Type II (Mobitz II) AV block and complete AV block
may be indications for pacing, certainly if bradycardia causeshypotension or heart failure. Revascularization should be
considered in non-reperfused patients. AV block associated
with inferior infarction is usually supra-Hisian (narrow QRS)
and rarely require interventions.
AV block associated with anterior STEMI is usually infra-
Hisian (wide QRS and low escape rhythm), and has a high
mortality rate due to the extensive myocardial necrosis. The
development of a new BBB or hemiblock usually indicates
extensive anterior infarction. A transvenous pacing is indi-
cated in advanced AV block with a low escape rhythm and
considered in bifascicular or trifascicular block.
Permanent pacing is indicated in patients with persistent
third-degree AV block, persistent second-degree AV block
associated with BBB, and transient Mobitz II or complete
heart block associated with new onset BBB.
5.3. Other cardiac complications
Life threatening mechanical complications may occur espe-
cially in patients at advanced age, with Killip II–IV symptoms,
3 vessel disease, anterior wall infarction, prolonged ischae-
mic time or reduced TIMI flow. At least twice daily clinical
examination and echocardiography are needed.
5.3.1. Mitral valve regurgitation
Pathophysiology: LV dilatation, papillary muscle dysfunction
or rupture.
Symptoms, diagnosis: sudden dyspnoea, pulmonary con-
gestion, new systolic murmur; emergency echocardiography
Therapy: intravenous diuretic and vasodilator/inotropic
support, IABP, angiography and emergent surgery
5.3.2. LV free wall rupture
Often fatal acute rupture of the LV free wall confirmed by
echocardiography may present as sudden pain and electro-
mechanical dissociation. Subacute free wall may permit time
for pericardiocentesis and immediate surgery.
5.3.3. Ventricular septal rupture
Symptoms, diagnosis: rapid onset clinical deterioration with
acute heart failure and a loud systolic murmur; echocar-
diography
Therapy: IABP, angiography and urgent surgery (no agree-
ment on the optimal timing), intravenous diuretics and
vasodilators should be used with caution.
Mortality remains high and is higher in patients with
infero-basal defects.
5.3.4. Right ventricular infarction
Pathophysiology: mostly in connection with inferior wall
STEMI.
Symptoms: triad of hypotension, clear lung fields and
raised jugular venous pressure Diagnosis: elevation of the
ST-segment 0.1 mV in V1 and V4R; echocardiography.
Therapy: fluid loading (diuretics and vasodilators should be
avoided); maintenance of sinus rhythm
5.3.5. Pericarditis
The incidence has decreased and manifests as recurrent
chest pain, usually sharp and related to posture and
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ST-segment re-elevation.
Diagnosis: pericardial rub (often absent due to effusion);
echocardiography
Therapy: high-dose of aspirin, paracetamol or colchicine
(steroids and long-term non-steroidal anti-inflammatory
drugs should be avoided); pericardiocentesis, if signs of
tamponade.
Anticoagulant therapy should be interrupted unless abso-
lutely indicated.
5.3.6. Left ventricular aneurysm
Pathophysiology: large, especially anterolateral wall STEMI,
remodelling, LV dysfunction followed frequently by mitral
regurgitation.
Diagnosis: echocardiography (wall-motions, mural throm-
bus detection).
Therapy: ACE inhibitors/ARBs and aldosterone antagonists
early following haemodynamic stabilization; chronic heart
failure therapy if needed
5.3.7. Left ventricular thrombus
LV thrombi are associated with poor prognosis but its fre-
quency has decreased during the reperfusion era. Consensus
is that mural thrombi, once diagnosed, require oral antic-6. Personal comment added by P. Widimsky´, P. K
During the ESC Congress 2012, after the ESC STEMI guidelines pub
Hot Lines: The ‘‘WOEST‘‘ trial (W. DeWilde et al.) has convincingly
oral anticoagulant therapy for other diagnosis (e.g. atrial fibrillat
warfarin), but rather a dual therapy with clopidogrel þ warfarin
published in N Engl J Med 2012, Aug 26 Epub ahead of print) did n
in patients with cardiogenic shock treated by primary PCI. The res
t ooagulant therapy for up to 6 months (3 months in patients
without further thrombi evidence on echocardiography).
However, this concept has not been revisited in the era of
stenting and DAPT. The bleeding risk during the triple
therapy‘‘ is increased and its optimal duration is unknown.
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